Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
1.090
-0.010 (-0.91%)
Apr 16, 2026, 11:10 AM EDT - Market open
Oncolytics Biotech Employees
Oncolytics Biotech had 29 employees as of December 31, 2025. The number of employees increased by 1 or 3.57% compared to the previous year.
Employees
29
Change (1Y)
1
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
-$991,690
Market Cap
126.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 1 | 3.57% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| PepGen | 56 |
| Equillium | 35 |
| Cardiff Oncology | 31 |
| Genelux | 26 |
| AN2 Therapeutics | 21 |
| ProMIS Neurosciences | 11 |
ONCY News
- 10 days ago - Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer - GlobeNewsWire
- 15 days ago - Oncolytics Biotech® Completes Domicile Change to the United States - GlobeNewsWire
- 4 weeks ago - Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - GlobeNewsWire
- 6 weeks ago - Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - GlobeNewsWire
- 7 weeks ago - Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer - GlobeNewsWire
- 2 months ago - Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer - GlobeNewsWire
- 3 months ago - Oncolytics Biotech® Announces Results of Special Meeting of Shareholders - GlobeNewsWire
- 3 months ago - Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer - GlobeNewsWire